🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. INFLIXIMAB, SODIUM CHLORIDE, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., DEXTROSE BP

    AstraZeneca AB

    Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)

    phase 3 small molecule active

    1 trial

  2. INT230-6

    INTENSITY THERAPEUTICS, INC.

    Sarcoma,Soft Tissue

    phase 3 small molecule active

    1 trial

  3. ION 682884, ION 682884

    IONIS PHARMACEUTICALS INC

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule active

    1 trial

  4. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  5. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  6. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical hemolytic uremic syndrome

    phase 3 small molecule active

    1 trial

  7. IPTACOPAN HYDROCHLORIDE

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  8. IPTACOPAN, LNP023

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  9. IRBESARTAN, DAPAGLIFLOZIN, Sparsentan_DF3, Sparsentan_DF2

    Travere Therapeutics

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  10. IRINOTECAN HYDROCHLORIDE, CAPECITABINE, OXALIPLATIN, CAPECITABINE, CALCIUM FOLINATE, FLUOROURACIL

    The George Institute

    Rectum cancer

    phase 3 small molecule active

    1 trial

  11. IRINOTECAN, REGORAFENIB, Stivarga 40 mg film-coated tablets

    The George Institute

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  12. ISIS 721744

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema

    phase 3 small molecule active

    1 trial

  13. ISIS 721744, ISIS 721744

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial

  14. ITF2357

    Italfarmaco S.p.A.

    Duchenne Muscular Dystrophy (DMD)

    phase 3 small molecule active

    1 trial

  15. IVEMEND 150 mg powder for solution for infusion, Aprepitant Placebo Tablet, Aprepitant Teva 80 mg, harde capsules, NaCl I.V.

    AXIM BIOTECHNOLOGIES, INC.

    Delayed chemotherapy induced nausea and vomiting (CINV)

    phase 3 small molecule active

    1 trial

  16. IVEMEND 150 mg powder for solution for infusion, fosnetupitant chloride 260 mg/palonosetron 1.5 mg, fosnetupitant chloride 260 mg/palonosetron 2.5 mg, Ondansetrone Hikma 8 mg/4 ml Soluzione iniettabile, Sodium Chloride Injection BP 0.9% w/v

    Helsinn Birex Pharmaceuticals Ltd

    Chemotherapy-induced nausea and vomiting

    phase 3 small molecule active

    1 trial

  17. Ibutamoren Mesylate, Ibutamoren Mesylate, Matched placebo capsules administered orally once per day, Ibutamoren Mesylate

    Lacuna Pharma Pty Ltd

    Growth Hormone Deficiency (GHD)

    phase 3 small molecule active

    1 trial

  18. Icatibant

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    3 trials

  19. Iclepertin

    Boehringer Ingelheim

    Schizophrenia

    phase 3 small molecule terminated

    2 trials

  20. Idefirix 11 mg powder for concentrate for solution for infusion

    Hansa Biopharma AB

    End stage chronic kidney disease (CKD) patients who are highly sensitised and on the kidney transplant list awaiting a kidney transplant

    phase 3 small molecule active

    1 trial

  21. Identical to kai-9531 solution for injection without active drug, KAI-9531, KAI-9531, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  22. Identical to the Test product, XGEVA 120 mg solution for injection

    Shanghai Reinovax Biologics Co.,LTD

    Prevention of breast cancer in women with a BRCA1 germline mutation

    phase 3 small molecule active

    1 trial

  23. Iduronate-2-sulfatase enzyme replacement therapy

    Takeda

    Mucopolysaccharidosis II

    phase 3 mab completed

    1 trial

  24. IkT-001Pro, Placebo to match 100 mg IKT-001 tablets

    Inhibikase Therapeutics

    Pulmonary Arterial Hypertension

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources